HCW Biologics Valuation
| HCWB Stock | USD 0.77 0.06 8.45% |
HCW Biologics is undervalued. HCW Biologics retains a regular Real Value of $2.05 per share. The prevalent price of the entity is $0.77. Our model calculates the value of HCW Biologics from analyzing the entity fundamentals such as return on asset of -0.7, and Current Valuation of 38.64 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting HCW Biologics' valuation include:
Price Book 2.7998 | Enterprise Value 38.6 M | Enterprise Value Ebitda (3.63) | Price Sales 6.8421 | Enterprise Value Revenue 11.054 |
Undervalued
Today
Please note that HCW Biologics' price fluctuation is out of control at this time. Calculation of the real value of HCW Biologics is based on 3 months time horizon. Increasing HCW Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since HCW Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HCW Stock. However, HCW Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.77 | Real 2.05 | Target 6.0 | Hype 0.81 | Naive 1.17 |
The real value of HCW Stock, also known as its intrinsic value, is the underlying worth of HCW Biologics Company, which is reflected in its stock price. It is based on HCW Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of HCW Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of HCW Biologics helps investors to forecast how HCW stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HCW Biologics more accurately as focusing exclusively on HCW Biologics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use HCW Biologics' intrinsic value based on its ongoing forecasts of HCW Biologics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against HCW Biologics' closest peers. If more than one evaluation category is relevant for HCW Biologics we suggest using both methods to arrive at a better estimate.
HCW Biologics Cash |
|
HCW Valuation Trend
Comparing HCW Biologics' enterprise value against its market capitalization is a good way to estimate the value of HCW Biologics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
HCW Biologics Total Value Analysis
HCW Biologics is currently anticipated to have valuation of 38.64 M with market capitalization of 11.95 M, debt of 6.3 M, and cash on hands of 32.41 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the HCW Biologics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
38.64 M | 11.95 M | 6.3 M | 32.41 M |
HCW Biologics Investor Information
About 52.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.05. HCW Biologics had not issued any dividends in recent years. Based on the key indicators related to HCW Biologics' liquidity, profitability, solvency, and operating efficiency, HCW Biologics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.HCW Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. HCW Biologics has an asset utilization ratio of 9.97 percent. This suggests that the Company is making $0.0997 for each dollar of assets. An increasing asset utilization means that HCW Biologics is more efficient with each dollar of assets it utilizes for everyday operations.HCW Biologics Ownership Allocation
HCW Biologics has a total of 37.82 Million outstanding shares. HCW Biologics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the entity is less than the current market value, you may not be able to make money on it.HCW Biologics Profitability Analysis
The company reported the previous year's revenue of 2.84 M. Net Loss for the year was (24.99 M) with profit before overhead, payroll, taxes, and interest of 4.1 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates HCW Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in HCW Biologics and how it compares across the competition.
About HCW Biologics Valuation
The stock valuation mechanism determines HCW Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of HCW Biologics. We calculate exposure to HCW Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HCW Biologics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -574.8 K | -546.1 K | |
| Pretax Profit Margin | (8.80) | (9.24) | |
| Operating Profit Margin | (9.05) | (9.50) | |
| Net Loss | (8.80) | (9.24) | |
| Gross Profit Margin | (0.20) | (0.19) |
HCW Biologics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 35.9 M |
HCW Biologics Current Valuation Indicators
Valuation refers to the process of determining the present value of HCW Biologics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value HCW we look at many different elements of the entity such as HCW's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as HCW Biologics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use HCW Biologics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes HCW Biologics' worth.Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |